Mass Spectrometry Center
Located in I-court (I – 093) of the Health Sciences Building on the University of Washington campus (click here for directions), the Mass Spectrometry Center is open-access self-sustaining instrument laboratory providing a wide variety of mass spectral services to the University and the research community-at-large (including commercial) on a recharge basis.
The Mass Spectrometry Center offers the following services:
- Instrument Training – Training services available to center users:
- Basic UPLC operation and gradient development
- Compound optimization for quantitative assays
- Basic mass spectrometry analysis on all center platforms
- Software training for quantitative and qualitative analysis software
- Submitted Sample Analysis – Examples of routine analysis include:
- High resolution accurate mass measurements of small molecules
- Lipids, proteins, and small molecules
- Protein digest peptide mapping (discovery proteomics)
- Whole protein mass determination
- LC-MS separations of complex mixtures
- Assay Development – Contracted development of quantitative (MRM) and qualitative assays:
- Complete quantitative assays including compound optimization and separation methods
- Extraction protocol development for quantitative assays including recovery calculations
- Calibration curve development for absolute quantification
- MRM Quantitative Proteomics – We offer support on quantitative proteomics including:
- Development of quantification methods and digests for proteins
- Quantification in tissues, cells, cell lines, biofluids
About the Center
The Center serves as a resource offering analytical and instructional expertise in contemporary mass spectrometric techniques and instrumentation with the primary aim of providing researchers with “hands-on” training and ready access to “state-of-the-art” instrumentation needed to develop and meet their research interests. Examples of routine analysis are: Low and High Resolution mass analysis, metabolomics, Metid, analyte quantitation, and structural elucidation.
Nelson CH, Buttrick BR, Isoherranen N. “Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.” Curr Top Med Chem. 2013; 13(12:1402-28).
Parkinson OT, Liggitt HD, Rettie AE, Kelly EJ. “Generalization and characterization of a CYP4B1 null mouse and the role of CYP4B1 in the activation and toxicity of Ipomeanol.” Toxicol Sci. 2013 Aug; 134(2):243-50. PubMed link.
McDermott CL, Sandmaier BM, Storer B, Li H, Mager DE, Boeckh MJ, Bemer MJ, Knutson J, McCune JS. “Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation.” Biol Blood Marrow Tranplant 2013 Aug; 19(8):1159-66.